Old Web
English
Sign In
Acemap
>
authorDetail
>
Inge Govaerts
Inge Govaerts
Katholieke Universiteit Leuven
Leukemia
Cancer research
T cell
Molecular biology
Mutation
5
Papers
22
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
2021
Journal of Hematology & Oncology
Inge Govaerts
Cristina Prieto
Charlien Vandersmissen
Olga Gielen
Kris Jacobs
Sarah Provost
David Nittner
Johan Maertens
Nancy Boeckx
Kim De Keersmaecker
Heidi Segers
Jan Cools
Show All
Source
Cite
Save
Citations (0)
JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
2019
Inge Govaerts
Kris Jacobs
Roel Vandepoel
Jan Cools
Show All
Source
Cite
Save
Citations (7)
Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing
2019
Blood
Llucia Alberti-Servera
Sofie Demeyer
Inge Govaerts
Olga Gielen
Heidi Segers
Anne Uyttebroeck
Nancy Boeckx
Johan Maertens
Kim De Keersmaecker
Jan Cools
Show All
Source
Cite
Save
Citations (0)
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia (vol 32, pg 788, 2018)
2018
Leukemia
Sandrine Degryse
C E de Bock
Sofie Demeyer
Inge Govaerts
Simon Bornschein
Delphine Verbeke
Kris Jacobs
S. Binos
David A. Skerrett-Byrne
Heather C. Murray
Nicole M. Verrills
Pieter Van Vlierberghe
Jan Cools
Matthew D. Dun
Show All
Source
Cite
Save
Citations (0)
1